John Crowley - Amicus Therapeutics Insider

FOLD -- USA Stock  

USD 15.75  0.99  5.91%

Chairman and CEO

Mr. John F. Crowley J.D. is the Chairman of the Board and Chief Executive Officer of Amicus Therapeutics, Inc. Mr. Crowley has served as Chairman and Chief Executive Officer since February 2010 and Chief Executive Officer since January 2005, except for the period during April 2011 through August 2011 during which time he served as Executive Chairman, Mr. Crowley has also served as a director of Amicus since August 2004, with the exception of the period from September 2006 to March 2007 when he was not an officer or director of Amicus while he was in active duty service in the United States Navy . Mr. Crowley was President and Chief Executive Officer of Orexigen Therapeutics, Inc. from September 2003 to December 2004. He was President and Chief Executive Officer of Novazyme Pharmaceuticals, Inc., from March 2000 until that company was acquired by Genzyme Corporationrationration in September 2001 thereafter he served as Senior Vice President of Genzyme Therapeutics until December 2002
Age: 49  Chairman Since 2011  MBA    
Crowley received a B.S. degree in Foreign Service from Georgetown University School of Foreign Service, a J.D. from the University of Notre Dame Law School, and an M.B.A. from Harvard Business School.

John Crowley Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (15.2) % which means that it has lost $15.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (79.66) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 164.47 M in liabilities with Debt to Equity (D/E) ratio of 46.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Amicus Therapeutics has Current Ratio of 5.49 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Entity Summary

Amicus Therapeutics, Inc., a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. Amicus Therapeutics, Inc. was founded in 2002 and is headquartered in Cranbury, New Jersey. Amicus Therapeutics operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 325 people.Amicus Therapeutics (FOLD) is traded on NASDAQ General Markets in USA. It is located in NEW JERSEY, U.S.A and employs 325 people. Amicus Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Amicus Therapeutics Leadership Team

Hung Do, President, Ph.D
Robert Essner, Director
John Kirk, President
Andrew Mulberg, President
Craig Wheeler, Director, MBA
Daphne Quimi, VP, MBA
Bradley Campbell, COO, MBA
Enrique Dilone, President
John Crowley, Chairman, MBA
Dipal Doshi, President, MBA
Mark Baldry, President
Margaret McGlynn, Director, MBA
Kenneth Peist, President
Ken Valenzano, President, Ph.D
Ted Love, Director
Jay Barth, Executive
Jayne Gershkowitz, President
Donald Hayden, Director, MBA
Michael Raab, Director
Sara Pellegrino, Executive
Willem Weperen, President
Sol Barer, Director
Julie Yu, President, MBA
William Baird, CFO, MBA
David Allsop, President
Ellen Rosenberg, Executive
Glenn Sblendorio, Director, MBA
Jeffrey Castelli, President, Ph.D
Kurt Andrews, President

Stock Performance Indicators

Did you try this?

Run Fund Screener Now

Fund Screener

Find activelly-traded funds from around the world traded on over 30 global exchanges
All  Next Launch Fund Screener

Generate Optimal Portfolios

Align your risk and return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally see Investing Opportunities. Please also try Coins and Tokens Correlation module to utilize digital token correlation table to build portfolio of cryptocurrencies across multiple exchanges.